Search Page

1

Cite

Share

Expanded antigen-experienced CD160⁺CD8⁺effector T cells exhibit impaired effector functions in chronic lymphocytic leukemia.

Bozorgmehr N, Okoye I, Oyegbami O, Xu L, Fontaine A, Cox-Kennett N, Larratt LM, Hnatiuk M, Fagarasanu A, Brandwein J, Peters AC, Elahi S. Bozorgmehr N, et al. Among authors: larratt lm. J Immunother Cancer. 2021 Apr;9(4):e002189. doi: 10.1136/jitc-2020-002189. J Immunother Cancer. 2021. PMID: 33931471 Free PMC article.

Cite

Share

2

Cite

Share

Valproic acid exerts differential effects on CXCR4 expression in leukemic cells.

Gul H, Marquez-Curtis LA, Jahroudi N, Larratt LM, Janowska-Wieczorek A. Gul H, et al. Among authors: larratt lm. Leuk Res. 2010 Feb;34(2):235-42. doi: 10.1016/j.leukres.2009.05.014. Epub 2009 Jun 18. Leuk Res. 2010. PMID: 19539992

Cite

Share

3

Cite

Share

Caterpillar-induced bleeding syndrome in a returning traveller.

Chan K, Lee A, Onell R, Etches W, Nahirniak S, Bagshaw SM, Larratt LM. Chan K, et al. Among authors: larratt lm. CMAJ. 2008 Jul 15;179(2):158-61. doi: 10.1503/cmaj.071844. CMAJ. 2008. PMID: 18625988 Free PMC article. No abstract available.

Cite

Share

4

Cite

Share

Membrane Type-1 Matrix Metalloproteinase Expression in Acute Myeloid Leukemia and Its Upregulation by Tumor Necrosis Factor-α.

Marquez-Curtis LA, Shirvaikar N, Turner AR, Mirza I, Surmawala A, Larratt LM, Janowska-Wieczorek A. Marquez-Curtis LA, et al. Among authors: larratt lm. Cancers (Basel). 2012 Jul 25;4(3):743-62. doi: 10.3390/cancers4030743. Cancers (Basel). 2012. PMID: 24213464 Free PMC article.

Cite

Share

5

Cite

Share

Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients.

Keats JJ, Maxwell CA, Taylor BJ, Hendzel MJ, Chesi M, Bergsagel PL, Larratt LM, Mant MJ, Reiman T, Belch AR, Pilarski LM. Keats JJ, et al. Among authors: larratt lm. Blood. 2005 May 15;105(10):4060-9. doi: 10.1182/blood-2004-09-3704. Epub 2005 Jan 27. Blood. 2005. PMID: 15677557 Free PMC article.

Cite

Share

6

Cite

Share

CD34+ cell responsiveness to stromal cell-derived factor-1alpha underlies rate of engraftment after peripheral blood stem cell transplantation.

Marquez-Curtis LA, Turner AR, Larratt LM, Letcher B, Lee SF, Janowska-Wieczorek A. Marquez-Curtis LA, et al. Among authors: larratt lm. Transfusion. 2009 Jan;49(1):161-9. doi: 10.1111/j.1537-2995.2008.01937.x. Epub 2008 Oct 2. Transfusion. 2009. PMID: 18954402

Cite

Share

7

Cite

Share

In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.

Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, Mant MJ, Belch AR, Pilarski LM. Keats JJ, et al. Among authors: larratt lm. Blood. 2003 Feb 15;101(4):1520-9. doi: 10.1182/blood-2002-06-1675. Epub 2002 Oct 3. Blood. 2003. PMID: 12393535 Free article.

Cite

Share

8

Cite

Share

5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.

O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki AB, Koziner B, Chanan-Khan AA, Seymour JF, Gribben J, Itri LM, Rai KR. O'Brien S, et al. Among authors: larratt lm. J Clin Oncol. 2009 Nov 1;27(31):5208-12. doi: 10.1200/JCO.2009.22.5748. Epub 2009 Sep 8. J Clin Oncol. 2009. PMID: 19738118 Free PMC article. Clinical Trial.

Cite

Share

9

Cite

Share

Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.

O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, Chanan-Khan AA, Seymour JF, Bociek RG, Pavletic S, Rai KR. O'Brien S, et al. Among authors: larratt lm. J Clin Oncol. 2007 Mar 20;25(9):1114-20. doi: 10.1200/JCO.2006.07.1191. Epub 2007 Feb 12. J Clin Oncol. 2007. PMID: 17296974 Clinical Trial.

Cite

Share